Atomwise, which uses AI to improve drug discovery, raises $45M Series A

TechCrunch | 3/7/2018 | Catherine Shu
Alenaaa (Posted by) Level 3
Click For Photo: https://tctechcrunch2011.files.wordpress.com/2018/03/atomwise-simulated-drug-research-2.png

Atomwise, which uses deep learning to shorten the process of discovering new drugs, has raised a $45 million Series A. The round was led by Monsanto Growth Ventures, Data Collective (DCVC) and B Capital Group. Baidu Ventures, Tencent and Dolby Family Ventures, which are all new investors in Atomwise, also participated, as well as returning investors Y Combinator, Khosla Ventures and DFJ.

This means Atomwise, which was founded in 2012, has now raised more than $51 million in funding. The company, which aims to reduce the amount of money and time researchers spend on finding compounds for medications, says it now has more than 50 molecular discovery programs. Atomwise’s technology is also being used to develop safer, more effective agricultural pesticides.

Press - Statement - Monsanto - Growth - Ventures

In a press statement, Monsanto Growth Ventures partner Dr. Kiersten Stead said “We chose to invest based on the impressive results we saw from Atomwise in our own hands. Atomwise was able to find promising compounds against crop protection targets that are important areas of focus for agrochemical R&D.”

Atomwise’s software analyzes simulations of molecules, reducing the time researchers need to spend synthesizing and testing compounds. The company says it currently screens more than 10 million compounds each day. Atomwise’s AtomNet system uses deep learning algorithms to analyze molecules and predict how they might act in the human body, including their potential efficacy as medication, toxicity and side effects, at an earlier stage than in the traditional drug discovery process.

Email - Atomwise - Executive - Officer - Dr

In an email, Atomwise chief executive officer Dr. Abraham Heifets told TechCrunch that the company’s vision “is to become one of the most prolific and diverse life science research groups in the world, working at a scale that is truly unprecedented. This is a large Series A and we will use these resources to...
(Excerpt) Read more at: TechCrunch
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!